India's leading research-based health management company with established research manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL) which was incorporated on 2nd February 1984 under the name of Panacea Drug (P) Ltd. A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management diabetes management renal-disease management anti-osteoporosis anti-tubercular gastro-intestinal care products and vaccines. The Company has collaborations and tie-ups with leading national and international research organizations and corporations. PBL has ultra modern state-of-art production facilities at Himachal Pradesh Punjab & Delhi for manufacturing vaccines and pharmaceutical formulations comply with the US-FDA UK-MHRA SAMCC and WHO-cGMP standards and it has four research and development centers. The Company also has 24 product patents valid in more than 60 countries worldwide. The plant for vaccines production (Radicura Pharma) and pharmaceutical formulations plant (Panacea Drug P Ltd) at New Delhi were established during the year 1988 and 1989 respectively. In 1993 merger of Panacea Drugs (P) Ltd and Radicura Pharma gave the name Panacea Biotec Ltd. The Company made its Initial Public Offering (IPO) in the year of 1995 and also in the same year PBL had formed state -of the- art Drug Delivery R&D centre at Lalru. In the year 1997 the company obtained its first product patent in several countries. PBL's Research & Development made a tie up with European MNC in the year 2001 and in 2002 an in-licensing agreement was made with Biotechnology Consortium of India for development & commercialization of Anthrax Vaccine. Also in the identical year of 2002 the company had commissioned Recombinant Vaccine production plant. During the year 2004 PBL made an in-licensing agreement with National Institute of Immunology New Delhi for Japanese Encephalitis Candidate Vaccine marketing joint venture with Chiron (now Novartis) Vaccines UK and also made collaboration with Cambridge Bio-stability UK for Thermo Stable Vaccines. After a year in 2005 an in-licensing agreement was prepared with National Institute of Health USA for Hair Growth Hormone. During the year 2006 ultra modern Pharmaceuticals formulation facility at Baddi Himachal Pradesh was goes live which has WHO cGMP complaint. Landmark collaborations were made with The Netherlands Vaccine Institute (The Nederlands Vaccin Institute (NVI)) for manufacture & marketing of finished Inactivated Polio Vaccine (IPV) and a number of IPV based combination vaccines in India and across the globe. Collaboration was happened with PT.Bio Farma to manufacture & market Measles Vaccine. Also in the same year of 2006 the company had inaugurated its Biopharmaceutical R&D Centre at New Delhi and made collaboration with National Research Development Corporation (NRDC) for technology transfer of Foot and Mouth Vaccine. Vaccine Formulation Plant of the company was established at Baddi in the year 2007 and the research agreement was made with Punjab University to develop New Chemical Entities for Psychiatric Disorders. PBL forayed into Healthcare Delivery in the year 2008 made a collaboration to set-up 220 bed multi super-specialty hospital in NCR and also the company obtained a patent (Patent No. 7371412 B2) from US Patent & Trademark Office for the product Thank GodTM (Euphorbia Prostrata) for effective management of hemorrhoids & piles in the identical year of 2008.